Browse studies

Find your next paid study

1 recruiting study matching your filters

An Open-Label, Randomized, Multicentre, Phase 2 Study of FOLFIRI + Bevacizumab + Pelareorep vs. FOLFIRI + Bevacizumab for the Second-Line Treatment of Metastatic, RAS-mutated, Microsatellite-Stable (MSS) Colorectal Cancer

This is an open-label, randomized, multicenter Phase 2 study to assess the efficacy and safety of FOLFIRI + bevacizumab + pelareorep vs. FOLFIRI + bevacizumab …

Ras-mutated Metastatic Colorectal CancermCRCMSS Metastatic Colorectal Cancer

Oncolytics BiotechNCT07446322